A Study To Evaluate PF-05175157 In Healthy Volunteers
This study has been completed.
Information provided by (Responsible Party):
First received: August 23, 2011
Last updated: May 16, 2012
Last verified: May 2012
The primary purpose of this study is to evaluate the pharmacodynamics of single oral doses of PF-05175157 in healthy volunteers
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
|Official Title:||Phase 1 Study To Evaluate The Effect Of Single Doses Of Pf-05175157 On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers|
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Changes in carbohydrate and lipid metabolism [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Pharmacokinetics: 0.5, 1, 1.5, 2.5, 6.5, 10.5, 24 hrs after dosing, parameters: Cmax, Tmax and Area under the Curve (AUC) [ Time Frame: 24 hours ] [ Designated as safety issue: No ]
|Study Start Date:||July 2011|
|Study Completion Date:||May 2012|
|Primary Completion Date:||May 2012 (Final data collection date for primary outcome measure)|
Experimental: 600 mg PF-05175157
Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
Placebo Comparator: Placebo
Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Contacts and Locations